Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. nanosil4cancer

NanoSil4Cancer

Smart Multifunctional silica-based Nanoparticles for Targeted Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 NanoSil4Cancer project word cloud

Explore the words cloud of the NanoSil4Cancer project. It provides you a very rough idea of what is the project "NanoSil4Cancer" about.

business    acid    pct    commercial    released    attractiveness    market    cells    290b    sparing    active    minimizing    limited    90    pharma    final    environmental    search    optimized    therapy    intracellular    report    receptor    nano    proprietary    chemotherapy    agents    overexpressing    vehicles    nanotechnologies    molecules    platform    efficacy    nevertheless    depends    toxicity    individuate    internalized    antitumor    feasibility    technologies    sensitive    normal    mesoporous    customers    nanoparticles    therapeutic    drug    ep06745236    folic    communication    fr    ph    accelerate    bortezomib    epo    minimize    dosage    patients    device    trend    smart    folate    prototype    13511    medical    customer    formulated    adherence    silica    sme    nanosil4cancer    lowering    strategical    compartments    buy    missing    healthcare    sectorial    thomson    patent    competence    release    innovative    drugs    stakeholder    cancer    pro    saving    marketing    interests    acquire    dramatically    big    prototypes   

Project "NanoSil4Cancer" data sheet

The following table provides information about the project.

Coordinator		 NANOSILICAL DEVICES SRL 

Organization address
address: VIA PIETRO BUCCI CUBO 44A
city: RENDE
postcode: 87036
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website http://www.nanosilicaldevices.com/it/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2017-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NANOSILICAL DEVICES SRL IT (RENDE) coordinator 50˙000.00

Map

 Project objective

NanoSil4Cancer project will be able to accelerate the uptake of nanotechnologies, by developing, mesoporous silica-based prototypes of nano-vehicles, according to an innovative and proprietary approach (EP06745236), active in smart chemotherapy. This is aimed to minimize toxicity and the side effects of the traditional antitumor agents and to increase their therapeutic potential. This technology platform enables customers’ molecules to be formulated as pH–sensitive pro-drugs and introduced in smart nanoparticles able to reach the intracellular compartments of cancer cells where the drug is released. Development of new prototypes will lead to new patent applications. Recently we have developed and optimized a device, provided with folic acid, able to manage bortezomib release in cancer cells overexpressing folate receptor, FR (PCT-13511). The nanoparticles are only recognized and internalized by FR overexpressing cancer cells, where they release the drug, sparing normal cells. Nevertheless, our technology is general, not limited to a specific prototype, but depends on customer's needs, market and final users' needs. The feasibility study will individuate strategical market interests to address the prototypes production as business opportunities for our SME. Market trend and the role of Big Pharma will be defined to identify commercial partners and stakeholder to be involved in the project. We will buy sectorial report, we will use patent search such as EPO and Thomson, we will acquire missing competence in marketing and communication. The approach will represent a strong step forward in chemotherapy, improving the efficacy, lowering drug dosage (thus minimizing side effects for cancer patients and environmental impact), other than dramatically lowering EU Healthcare costs (up to 80-90% saving on non-adherence to the therapy costs, estimated in $290B/year), allowing Europe to increase its attractiveness in the field of innovative medical technologies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSIL4CANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSIL4CANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More